Sofosbuvir, Velpatasvir Effective In Most Patients With HCV Regardless Of Cirrhosis Status, Results Show

Infectious Disease Advisor (7/14, Nye) reports, “Sustained virologic response at 12 weeks was achieved by sofosbuvir/velpatasvir dual therapy among most study patients with hepatitis C virus (HCV) infection, irrespective of cirrhosis status,” results publ...